离体肝切除联合自体肝移植术后的结局:系统评价与Meta分析
Meta分析显示R0切除率93.4%,主要手术并发症发生率24.5%,30天死亡率9.5%,1年生存率78.4%。个体数据分析显示恶性与良性肿瘤在1年生存率上差异显著(65.0% vs 89.7%,P<.001),良性肿瘤结局更优。
要点
- 离体肝切除联合自体肝移植可使部分常规不可切除肝肿瘤获得R0切除,R0率达93.4%。
- 该手术30天死亡率为9.5%,主要手术并发症发生率为24.5%,需重视围术期风险。
- 恶性肿瘤患者术后1年生存率(65.0%)显著低于良性肿瘤患者(89.7%)。
核心结论
- 离体肝切除联合自体肝移植可使筛选后的常规不可切除肝肿瘤且肝功能正常患者获得根治性治疗,但恶性病变的结局相对较差。
主要发现
- Meta分析显示R0切除率93.4%(95%CI 81.0-97.9%,I2=0%),主要手术并发症发生率24.5%(95%CI 16.9-34.3%,I2=26%),30天死亡率9.5%(95%CI 5.9-14.9%,I2=0%),1年生存率78.4%(95%CI 62.2-88.8%,I2=64%)。
- 个体数据分析中,R0切除率98.6%,各亚组间无明显差异;30天死亡率和1年生存率分别为7.9%和82.1%。
- 恶性 vs 非恶性肿瘤组:30天死亡率11.3% vs 6.3%(P=.181),1年生存率65.0% vs 89.7%(P<.001),主要手术并发症发生率50.0% vs 21.0%(P<.001)。
- 回归分析显示良性肿瘤患者结局优于恶性肿瘤患者(1年生存率,比值比4.629;95%CI 2.181-10.097,P<.001)。
临床怎么用
- 对于常规方法难以切除、肝功能正常的精选肝肿瘤患者,可考虑离体肝切除联合自体肝移植以实现根治性切除。
- 术前应充分评估肿瘤良恶性,恶性病变患者术后结局相对较差,需加强围术期管理和术后随访。
局限性
- Meta分析中1年生存率存在显著异质性(I2=64%)。
- 个体参与者数据仅来自244例患者,并非全部研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with hepatic tumors cannot benefit from resection owing to the difficult anatomic sites of their lesions. Some of these patients might be eligible for ex vivo liver resection and autotransplantation. This procedure consists of complete hepatectomy, extracorporeal liver resection, and autotransplantation of the remnant liver. METHODS: Four databases were searched for studies reporting cases of ex vivo liver resection and autotransplantation. Outcomes of this procedure were evaluated by meta-analysis of proportions with random effects model and individual participant data analysis. RESULTS: Fifty-three studies were assessed. Meta-analysis revealed an R0 resection rate of 93.4% (95% confidence interval: 81.0-97.9%, I2 = 0%), a frequency of major surgical complications of 24.5% (95% confidence interval, 16.9-34.3%, I2 = 26%), a 30-day mortality of 9.5% (95% confidence interval: 5.9-14.9%, I2 = 0%), and a 1-year survival of 78.4% (95% confidence interval: 62.2-88.8%, I2 = 64%). We were able to obtain the individual participant data in 244 patients; R0 resection was achieved in 98.6%, with no obvious difference between analyzed subgroups. The 30-day mortality and 1-year survivals were 7.9% and 82.1%, respectively. For groups with malignant and nonmalignant tumors, the 30-day mortalities were 11.3% vs. 6.3% (P = .181), and 1-year survivals were 65.0% vs. 89.7% (P < .001). When comparing those with malignant versus those with nonmalignant lesions, major surgical complications occurred in 50.0% vs. 21.0%; P < .001). Regression analysis revealed that outcomes of patients with benign tumors were better compared with those with malignant tumors (1-year survival, odds ratio: 4.629; 95% confidence interval: 2.181-10.097, P < .001). CONCLUSION: Ex vivo liver resection and autotransplantation facilitates radical treatment in selected patients with conventionally unresectable hepatic tumors and normal liver function. The outcomes of treatment of malignant lesions appear to be less satisfactory.
引用
- Zawistowski M, Nowaczyk J, Jakubczyk M, et al. Outcomes of ex vivo liver resection and autotransplantation: A systematic review and meta-analysis. Surgery. 2020. PMID: 32727659. doi:10.1016/j.surg.2020.05.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。